Bangkok: The Thai Food and Drug Administration (FDA) has issued a strong warning regarding the misuse of "weight-loss injection pens," highlighting the potential health risks associated with their misuse. The FDA has raised concerns about the growing trend on social media platforms promoting these injections, as individuals are self-administering dose adjustments and employing improper injection methods. This misuse poses significant health risks, including the possibility of a rapid weight regain known as the "yo-yo effect" and other severe side effects. The FDA stresses that such medications should only be used under the guidance and supervision of a qualified medical professional.
According to Thai News Agency, Pharmacist Supatra Boonsearm, the Secretary-General of the FDA, expressed alarm over the increasing popularity of "weight-loss injection pens" being advertised on social media. These products, especially when self-administered, can lead to dangerous health consequences. In Thailand, Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are officially approved solely for type 2 diabetes and obesity-related weight loss treatments, not for cosmetic weight-loss purposes. GLP-1 RAs function by promoting a feeling of fullness and reducing appetite, resulting in temporary weight loss. However, incorrect usage or abrupt discontinuation can cause rapid weight regain and serious side effects, including hypoglycemia, kidney failure, gallbladder inflammation, depression, or muscle atrophy. These risks are heightened for individuals with pre-existing conditions such as kidney or liver disease, thyroid disorders, or endocrine issues, necessitating strict medical oversight.
The Thai FDA has previously encountered illegal advertising and sales of these drugs, particularly online, and has taken legal action against offenders. Despite these efforts, misuse remains prevalent. Currently, the FDA is advocating for the Ministry of Public Health to reclassify GLP-1 RA drugs as "special controlled drugs," limiting their sale to pharmacies with a valid prescription from a doctor. This would also require pharmacies to keep detailed records and reports on drug sales to facilitate effective oversight.
The FDA's Secretary-General cautions the public against being deceived by advertisements promoting "weight loss through injections," emphasizing that there is no quick fix for safe and sustainable weight reduction. Effective weight loss should result from lifestyle modifications, including a balanced diet, regular exercise, adequate rest, and maintaining good mental health. These practices not only aid in weight management but also help prevent chronic non-communicable diseases in the long term.